{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:15:17Z","timestamp":1780992917164,"version":"3.54.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,7,23]],"date-time":"2016-07-23T00:00:00Z","timestamp":1469232000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s11255-016-1380-2","type":"journal-article","created":{"date-parts":[[2016,7,23]],"date-time":"2016-07-23T08:43:57Z","timestamp":1469263437000},"page":"1811-1816","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?"],"prefix":"10.1007","volume":"48","author":[{"given":"Mohmad Hussain","family":"Mir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid Hamid","family":"Changal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiekh Aejaz","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gull Mohammad","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rashid","family":"Lone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,23]]},"reference":[{"key":"1380_CR1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3109\/07357900903287022","volume":"28","author":"J Liu","year":"2010","unstructured":"Liu J, Mittendorf T, von der Schulenburg JM (2010) A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia. Cancer Invest 28:312\u2013322","journal-title":"Cancer Invest"},{"key":"1380_CR2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2007.12.001","volume":"34","author":"K Gupta","year":"2008","unstructured":"Gupta K, Miller JD, Li JZ et al (2008) Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34:193\u2013205","journal-title":"Cancer Treat Rev"},{"key":"1380_CR3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.2011-S2-04","volume":"16","author":"DS Finley","year":"2011","unstructured":"Finley DS, Pantuck AJ, Belldegrun AS (2011) Tumor biology and prognostic factors in RCC. Oncologist 16:4\u201313","journal-title":"Oncologist"},{"key":"1380_CR4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1634\/theoncologist.2011-S2-23","volume":"16","author":"D Cella","year":"2011","unstructured":"Cella D (2011) Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma. Oncologist 16:23\u201331","journal-title":"Oncologist"},{"issue":"Suppl 2","key":"1380_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1634\/theoncologist.2011-S2-14","volume":"16","author":"TE Hutson","year":"2011","unstructured":"Hutson TE (2011) Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 16(Suppl 2):14\u201322. doi: 10.1634\/theoncologist.2011-S2-14","journal-title":"Oncologist"},{"key":"1380_CR6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1380_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/bjc.2015.196","volume":"113","author":"ME Gore","year":"2015","unstructured":"Gore ME, Szczylik C, Porta C et al (2015) Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer 113(1):12\u201319. doi: 10.1038\/bjc.2015.196","journal-title":"Br J Cancer"},{"issue":"22","key":"1380_CR8","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584\u20133590. doi: 10.1200\/JCO.2008.20.1293","journal-title":"J Clin Oncol"},{"key":"1380_CR9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/01.rli.0000124457.99229.bb","volume":"39","author":"V Rouffiac","year":"2004","unstructured":"Rouffiac V, Bouquet C, Lassau N et al (2004) Validation of a new method for quantifying in vivo murine tumor necrosis by sonography. Invest Radiol 39:350\u2013356","journal-title":"Invest Radiol"},{"key":"1380_CR10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","volume":"6","author":"C Robert","year":"2005","unstructured":"Robert C, Soria JC, Spatz A et al (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6:491\u2013500","journal-title":"Lancet Oncol"},{"key":"1380_CR11","volume-title":"SUTENT product monograph","author":"Pfizer Canada Inc","year":"2006","unstructured":"Pfizer Canada Inc (2006) SUTENT product monograph. Pfizer Inc., Canada"},{"issue":"15 suppl","key":"1380_CR12","first-page":"163s","volume":"26","author":"BI Rini","year":"2008","unstructured":"Rini BI, Schiller JH, Fruehauf JP et al (2008) Association of diastolic blood pressure (dBP) >90\u00a0mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). J Clin Oncol 26(15 suppl):163s","journal-title":"J Clin Oncol"},{"issue":"1","key":"1380_CR13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bju.12940","volume":"117","author":"J Rautiola","year":"2016","unstructured":"Rautiola J, Donskov F, Peltola K (2016) Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma. BJU Int 117(1):110\u2013117","journal-title":"BJU Int"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-016-1380-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-016-1380-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-016-1380-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T19:04:04Z","timestamp":1498331044000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-016-1380-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,23]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["1380"],"URL":"https:\/\/doi.org\/10.1007\/s11255-016-1380-2","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,23]]}}}